NCT00264602Active, not recruitingPhase 1
Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer
Source: ClinicalTrials.gov · Last updated 10 Nov 2025
Brief summary (registry, in English)
The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- First submitted
- 12 Dec 2005
- Start date
- 18 Feb 2009
- Primary completion date
- 1 Sept 2017
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Lung cancer
- NCT number
- NCT00264602
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 57
- From 18 Feb 2009 to the primary completion date, 1 Sept 2017
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient does not want to undergo subsequent surgical resection
- Pre-operative spirometry that suggests they cannot undergo resection of their primary tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomy
Other illness
- Medical condition such as uncontrolled infection or cardiac disease that, i the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient.
- T4 or N2 disease
- Iodide or seafood allergy
Other
- Pregnant or lactating women
Who the study is looking for
- Suspected or histologically documented new non-small cell carcinoma that have agreed to undergo a thoracotomy for segmentectomy, lobectomy, bilobectomy or pneumonectomy as recommended by their thoracic surgeon for treatment
- Surgically resectable lung cancer
- N2 lymph nodes negative on PET scan or mediastinoscopy
- Age \> or equal to 18 years of age
- Men, women of non-child bearing age or women with a negative pregnancy test
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.